AU2007254831B2 - High affinity antibodies to human IL-6 receptor - Google Patents
High affinity antibodies to human IL-6 receptor Download PDFInfo
- Publication number
- AU2007254831B2 AU2007254831B2 AU2007254831A AU2007254831A AU2007254831B2 AU 2007254831 B2 AU2007254831 B2 AU 2007254831B2 AU 2007254831 A AU2007254831 A AU 2007254831A AU 2007254831 A AU2007254831 A AU 2007254831A AU 2007254831 B2 AU2007254831 B2 AU 2007254831B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 102000005962 receptors Human genes 0.000 title abstract description 14
- 108020003175 receptors Proteins 0.000 title abstract description 14
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 title abstract description 5
- 102000052611 human IL6 Human genes 0.000 title abstract description 5
- 230000027455 binding Effects 0.000 claims abstract description 90
- 102000036639 antigens Human genes 0.000 claims abstract description 83
- 108091007433 antigens Proteins 0.000 claims abstract description 83
- 239000000427 antigen Substances 0.000 claims abstract description 82
- 239000012634 fragment Substances 0.000 claims abstract description 59
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 14
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 14
- 210000004027 cell Anatomy 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 102000052623 human IL6R Human genes 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 abstract description 16
- 241000282693 Cercopithecidae Species 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 13
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 abstract description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000004408 hybridoma Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 125000003729 nucleotide group Chemical group 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 108010051219 Cre recombinase Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- -1 X 3 = lie Chemical compound 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101100496169 Arabidopsis thaliana CLH1 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 1
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241001435619 Lile Species 0.000 description 1
- 238000012491 Luciferase Bioassay Methods 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101100044057 Mesocricetus auratus SYCP3 gene Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100080600 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nse6 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 101150111293 cor-1 gene Proteins 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81066406P | 2006-06-02 | 2006-06-02 | |
| US60/810,664 | 2006-06-02 | ||
| US84323206P | 2006-09-08 | 2006-09-08 | |
| US60/843,232 | 2006-09-08 | ||
| PCT/US2007/013062 WO2007143168A2 (en) | 2006-06-02 | 2007-06-01 | High affinity antibodies to human il-6 receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007254831A1 AU2007254831A1 (en) | 2007-12-13 |
| AU2007254831B2 true AU2007254831B2 (en) | 2012-03-22 |
Family
ID=38792460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007254831A Active 2032-06-01 AU2007254831B2 (en) | 2006-06-02 | 2007-06-01 | High affinity antibodies to human IL-6 receptor |
Country Status (33)
| Country | Link |
|---|---|
| US (10) | US7582298B2 (OSRAM) |
| EP (2) | EP2374818B1 (OSRAM) |
| JP (3) | JP5307708B2 (OSRAM) |
| KR (1) | KR101464502B1 (OSRAM) |
| CN (2) | CN102585002A (OSRAM) |
| AT (1) | ATE537190T1 (OSRAM) |
| AU (1) | AU2007254831B2 (OSRAM) |
| BR (1) | BRPI0712224B8 (OSRAM) |
| CA (1) | CA2652976C (OSRAM) |
| CR (1) | CR10462A (OSRAM) |
| CY (3) | CY1112456T1 (OSRAM) |
| DK (2) | DK2041177T3 (OSRAM) |
| ES (2) | ES2398076T3 (OSRAM) |
| GT (1) | GT200800272A (OSRAM) |
| HR (2) | HRP20120175T1 (OSRAM) |
| HU (1) | HUS1700050I1 (OSRAM) |
| IL (1) | IL195393A (OSRAM) |
| LT (1) | LTC2041177I2 (OSRAM) |
| LU (1) | LUC00050I2 (OSRAM) |
| ME (1) | ME00519B (OSRAM) |
| MX (1) | MX2008014804A (OSRAM) |
| MY (2) | MY147468A (OSRAM) |
| NL (1) | NL300911I2 (OSRAM) |
| NO (2) | NO340778B1 (OSRAM) |
| NZ (2) | NZ573557A (OSRAM) |
| PL (2) | PL2374818T3 (OSRAM) |
| PT (2) | PT2374818E (OSRAM) |
| RS (2) | RS52176B (OSRAM) |
| RU (1) | RU2433138C2 (OSRAM) |
| SI (2) | SI2041177T1 (OSRAM) |
| SV (1) | SV2008003113A (OSRAM) |
| TN (1) | TNSN08502A1 (OSRAM) |
| WO (1) | WO2007143168A2 (OSRAM) |
Families Citing this family (379)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| EP2395017A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| KR101239051B1 (ko) | 2005-10-21 | 2013-03-04 | 추가이 세이야쿠 가부시키가이샤 | 심장질환 치료제 |
| EP2006381B1 (en) * | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
| WO2007116962A1 (ja) | 2006-04-07 | 2007-10-18 | Osaka University | 筋再生促進剤 |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| AU2007285695B2 (en) * | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| JP2010510796A (ja) * | 2006-11-30 | 2010-04-08 | アストラゼネカ アクチボラグ | インターロイキン−６とインターロイキン−６受容体との複合体に特異的な抗体 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| ES2564392T3 (es) | 2007-01-23 | 2016-03-22 | Shinshu University | Inhibidores de IL-6 para el tratamiento de rechazo crónico |
| US8178101B2 (en) * | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8404235B2 (en) * | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| CN105001332B (zh) | 2007-05-21 | 2018-12-04 | 奥尔德生物控股有限责任公司 | 针对il-6的抗体及其用途 |
| KR20100028571A (ko) * | 2007-05-21 | 2010-03-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체 |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| BRPI0815370B8 (pt) | 2007-08-10 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica |
| RU2505603C2 (ru) | 2007-09-26 | 2014-01-27 | Чугаи Сейяку Кабусики Кайся | Антитело против рецептора il-6 |
| CL2008002886A1 (es) * | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. |
| CA2700701C (en) | 2007-09-26 | 2020-12-29 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
| NZ717429A (en) | 2008-04-11 | 2018-07-27 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| US8034344B2 (en) | 2008-05-13 | 2011-10-11 | Novimmune S.A. | Anti-IL-6/IL-6R antibodies and methods of use thereof |
| WO2009143472A2 (en) * | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
| KR101665729B1 (ko) | 2008-06-05 | 2016-10-12 | 국립연구개발법인 고쿠리츠간켄큐센터 | 신경침윤 억제제 |
| EP2556747B1 (en) | 2008-06-27 | 2020-12-02 | Merus N.V. | Antibody producing transgenic mice |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| AU2012200724B8 (en) * | 2008-09-26 | 2014-09-11 | Chugai Seiyaku Kabushiki Kaisha | Improved antibody molecules |
| WO2010056948A2 (en) | 2008-11-13 | 2010-05-20 | Femta Pharmaceuticals, Inc. | Humanized anti-il-6 antibodies |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CA2744103C (en) | 2009-02-24 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods for identifying immunobinders of cell-surface antigens |
| SG10201408247SA (en) * | 2009-02-24 | 2015-02-27 | Esbatech Alcon Biomed Res Unit | Methods for identifying immunobinders of cell-surface antigens |
| EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| WO2010106812A1 (en) * | 2009-03-19 | 2010-09-23 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical formulation containing improved antibody molecules |
| WO2010107110A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| EP2417162A2 (en) * | 2009-04-10 | 2012-02-15 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| WO2010115998A2 (en) | 2009-04-10 | 2010-10-14 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| PT2564695E (pt) | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| HRP20240920T1 (hr) | 2009-10-26 | 2024-10-11 | F. Hoffmann - La Roche Ag | Postupak za proizvodnju glikoziliranog imunoglobulina |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| US20120294852A1 (en) | 2009-11-24 | 2012-11-22 | Smith Jeffrey T L | Antagonists of il-6 to raise albumin and/or lower crp |
| CN104131035A (zh) | 2009-12-10 | 2014-11-05 | 瑞泽恩制药公司 | 生产重链抗体的小鼠 |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| DK2505654T4 (da) | 2010-02-08 | 2020-07-27 | Regeneron Pharma | Mus med fælles letkæde |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| EP3190187A1 (en) * | 2010-05-21 | 2017-07-12 | Peptimed, Inc. | Reagents and methods for treating cancer |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| PL2578231T3 (pl) | 2010-05-28 | 2023-01-16 | Chugai Seiyaku Kabushiki Kaisha | Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t |
| KR101900435B1 (ko) | 2010-06-16 | 2018-09-20 | 트렐리스 바이오싸이언스 인코포레이티드 | 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 |
| CA3250882A1 (en) | 2010-08-02 | 2025-11-29 | Regeneron Pharamaceuticals, Inc. | Mice that Make Binding Proteins Comprising VL Domains |
| AR083044A1 (es) * | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| US9533039B2 (en) | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
| CN108715614A (zh) | 2010-11-30 | 2018-10-30 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| WO2012098238A1 (en) | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| MX366458B (es) | 2011-01-28 | 2019-07-10 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
| SI2738258T2 (sl) | 2011-02-25 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Miši ADAM6 |
| JP6097702B2 (ja) * | 2011-03-03 | 2017-03-15 | アペクシジェン， インコーポレイテッド | 抗ｉｌ−６受容体抗体およびその使用方法 |
| US11028149B2 (en) | 2011-04-01 | 2021-06-08 | Chugai Seiyaku Kabushiki Kaisha | Recombinant polypeptide production method |
| DK2527842T3 (da) | 2011-05-12 | 2013-09-08 | Regeneron Pharma | Neuropeptidfrisætningsanalyse til natriumkanaler |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
| WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| CA2849195A1 (en) | 2011-09-23 | 2013-03-28 | Ablynx Nv | Prolonged inhibition of interleukin-6 mediated signaling |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| ES2694153T3 (es) | 2011-09-30 | 2018-12-18 | Regeneron Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 y usos de los mismos |
| KR20200039028A (ko) * | 2011-10-11 | 2020-04-14 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| MY172946A (en) | 2011-10-17 | 2019-12-16 | Regeneron Pharma | Restricted immunoglobulin heavy chain mice |
| WO2013059548A1 (en) | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
| WO2013059426A1 (en) * | 2011-10-21 | 2013-04-25 | The Regents Of The University Of California | Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof |
| CN103059137A (zh) * | 2011-10-21 | 2013-04-24 | 神州细胞工程有限公司 | 抗hIL6R高亲和力抗体的制备及应用 |
| RS55949B1 (sr) | 2011-10-28 | 2017-09-29 | Regeneron Pharmaeuticals Inc | Humanizovani il-6 i il-6 receptor |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| EP2780368B1 (en) | 2011-11-14 | 2018-01-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a |
| PL2782598T3 (pl) | 2011-11-23 | 2021-03-08 | In3Bio Ltd. | Rekombinowane białka i ich zastosowania terapeutyczne |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| KR102081657B1 (ko) | 2011-12-20 | 2020-02-26 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
| HUE056335T2 (hu) * | 2012-01-31 | 2022-02-28 | Regeneron Pharma | ASIC1-ellenes antitestek és alkalmazásaik |
| US9371383B2 (en) | 2012-01-31 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| TWI613215B (zh) | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 |
| CN104203976A (zh) | 2012-03-02 | 2014-12-10 | 瑞泽恩制药公司 | 艰难梭状芽孢杆菌毒素的人源抗体 |
| JP2015509380A (ja) | 2012-03-06 | 2015-03-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 共通の軽鎖のマウス |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| ES2665793T3 (es) | 2012-03-16 | 2018-04-27 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de cadena ligera modificada mediante ingeniería genética con histidina y roedores modificados genéticamente para la generación de los mismos |
| CN104302170B (zh) | 2012-03-16 | 2016-09-28 | 瑞泽恩制药公司 | 生产具有ph依赖性结合特性的抗原结合蛋白的小鼠 |
| NZ730271A (en) | 2012-03-16 | 2022-09-30 | Regeneron Pharma | Non-human animals expressing ph-sensitive immunoglobulin sequences |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CA2870821C (en) | 2012-04-20 | 2022-06-14 | Merus B.V. | Methods and means for the production of ig-like molecules |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| HUE055617T2 (hu) | 2012-06-12 | 2021-12-28 | Regeneron Pharma | Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények |
| TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| KR102307248B1 (ko) | 2012-08-21 | 2021-10-01 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| NZ630178A (en) | 2012-09-07 | 2017-06-30 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US20140134189A1 (en) | 2012-11-13 | 2014-05-15 | Regeneron Pharmaceuticals, Inc. | Anti-prokineticin receptor (prokr) antibodies and uses thereof |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| ES2678221T3 (es) | 2013-02-20 | 2018-08-09 | Regeneron Pharmaceuticals, Inc. | Animales no humanos con secuencias de cadena pesada de inmunoglobulina modificadas |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| LT3501272T (lt) | 2013-03-13 | 2023-03-27 | Regeneron Pharmaceuticals, Inc. | Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką |
| EP2970437A1 (en) | 2013-03-13 | 2016-01-20 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| HK1220468A1 (zh) | 2013-03-14 | 2017-05-05 | Regeneron Pharmaceuticals, Inc. | Nav1．7的人抗体 |
| MX369574B (es) | 2013-03-14 | 2019-11-13 | Regeneron Pharma | Anticuerpos humanos contra grem1. |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| EP3009518B1 (en) | 2013-06-11 | 2020-08-12 | National Center of Neurology and Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy |
| MX368068B (es) | 2013-06-21 | 2019-09-18 | Sanofi Biotechnology | Antagonista de il-4r para usarse para tratar la poliposis nasal. |
| TW201920262A (zh) | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| WO2015027154A2 (en) | 2013-08-23 | 2015-02-26 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| SG10201810825YA (en) | 2013-09-18 | 2019-01-30 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| NL2013554B1 (en) | 2013-10-01 | 2016-01-08 | Kymab Ltd | Animal models and therapeutic molecules. |
| WO2015066259A1 (en) | 2013-10-31 | 2015-05-07 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| EA201691027A1 (ru) | 2013-11-20 | 2016-12-30 | Ридженерон Фармасьютикалз, Инк. | Модуляторы aplnr и их применение |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| WO2015095511A2 (en) * | 2013-12-20 | 2015-06-25 | The Scripps Research Institute | Functional antibodies that modulate cell death and related methods |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| WO2015116852A1 (en) | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| CN106459199B (zh) | 2014-03-11 | 2021-01-01 | 瑞泽恩制药公司 | 抗-egfrviii抗体及其用途 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| BR112016021679A2 (pt) | 2014-03-21 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado. |
| BR112016021572A2 (pt) | 2014-03-21 | 2017-10-03 | Regeneron Pharma | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| JP2017533695A (ja) | 2014-09-16 | 2017-11-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗グルカゴン抗体およびその使用 |
| SG10201913084PA (en) | 2014-09-23 | 2020-03-30 | Regeneron Pharma | Anti-il-25 antibodies and uses thereof |
| AU2015334984A1 (en) | 2014-10-21 | 2017-04-13 | Ablynx Nv | Treatment of IL-6R related diseases |
| CA2967602C (en) | 2014-11-14 | 2024-09-24 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATMENT OF CHRONIC SINUSITIS WITH NASAL POLYPOSIS BY ADMINISTRATION OF AN IL-4R ANTAGONIST |
| SMT202000438T1 (it) | 2014-11-17 | 2020-09-10 | Regeneron Pharma | Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20 |
| AU2015355150A1 (en) * | 2014-12-02 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods for treating dry eye disease by administering an IL-6R antagonist |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| EP4269440A3 (en) | 2015-02-27 | 2024-02-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| IL255010B2 (en) | 2015-04-15 | 2024-01-01 | Regeneron Pharma | Methods of increasing strength and functionality with gdf8 inhibitors |
| JP2016208934A (ja) * | 2015-05-12 | 2016-12-15 | 学校法人日本大学 | 抗イヌインターロイキン−６受容体モノクローナル抗体又は抗体フラグメント及びその利用 |
| EP3299810B1 (en) | 2015-05-19 | 2021-07-07 | National Center of Neurology and Psychiatry | Method for determining application of novel therapy to multiple sclerosis (ms) patient |
| US11174317B2 (en) | 2015-06-04 | 2021-11-16 | National Center Of Neurology And Psychiatry | Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient |
| JP6993958B2 (ja) | 2015-07-06 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多重特異性抗原結合分子およびその使用 |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| TWI870789B (zh) | 2015-08-04 | 2025-01-21 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| EA201890519A1 (ru) | 2015-08-18 | 2018-07-31 | Ридженерон Фармасьютикалз, Инк. | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| IL313952A (en) | 2015-12-22 | 2024-08-01 | Regeneron Pharma | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment |
| MX2018007781A (es) | 2015-12-28 | 2018-09-05 | Chugai Pharmaceutical Co Ltd | Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc). |
| SG10201914034WA (en) | 2016-01-13 | 2020-03-30 | Regeneron Pharma | Rodents having an engineered heavy chain diversity region |
| US20170247436A1 (en) | 2016-02-16 | 2017-08-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a mutant kynureninase gene |
| SG11201807614SA (en) | 2016-03-07 | 2018-10-30 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| EP3216461A1 (en) | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| MX386832B (es) | 2016-04-08 | 2025-03-19 | Regeneron Pharma | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. |
| BR112018071283A2 (pt) * | 2016-04-20 | 2019-02-12 | Regeneron Pharma | célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno. |
| CA3015371A1 (en) * | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| EP3448891A1 (en) | 2016-04-28 | 2019-03-06 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| JP7324583B2 (ja) | 2016-05-20 | 2023-08-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 複数のガイドｒｎａを使用して免疫寛容を破綻させるための方法 |
| WO2017201731A1 (en) * | 2016-05-27 | 2017-11-30 | Beijing Vdjbio Co., Ltd. | Antibodies, composition and kits comprising same, and methods of use thereof |
| WO2017214089A1 (en) | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| BR112018075434A2 (pt) | 2016-06-10 | 2019-03-19 | Regeneron Pharmaceuticals, Inc. | anticorpo isolado ou fragmento de ligação de antígeno do mesmo, composição farmacêutica, e, métodos para tratar câncer e para modular resposta imune antitumor. |
| EP4374922A3 (en) | 2016-06-14 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| RU2656160C2 (ru) * | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| US11771743B2 (en) | 2016-09-01 | 2023-10-03 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an IL-4R antagonist |
| MY199468A (en) | 2016-09-23 | 2023-10-31 | Regeneron Pharma | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof |
| PT3515946T (pt) | 2016-09-23 | 2022-08-04 | Regeneron Pharma | Anticorpos anti-muc16 (mucin 16) |
| DK3766343T3 (da) | 2016-11-04 | 2022-06-20 | Regeneron Pharma | Ikke-humane dyr med et manipuleret immunoglobulin-lambda-letkædelocus |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| CN110036029A (zh) | 2016-11-17 | 2019-07-19 | 瑞泽恩制药公司 | 用抗angptl8抗体处理肥胖的方法 |
| EA201991283A9 (ru) | 2016-11-29 | 2019-11-27 | Фармацевтическая композиция для предотвращения опиоидной зависимости | |
| MX2019006131A (es) | 2016-11-29 | 2019-08-21 | Regeneron Pharma | Metodos para tratar cancer de mama positivo para prlr. |
| MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| WO2018118713A1 (en) | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| MY200034A (en) | 2017-02-10 | 2023-12-05 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
| KR102674000B1 (ko) | 2017-06-01 | 2024-06-11 | 리제너론 파마슈티칼스 인코포레이티드 | Bet v 1에 대한 인간 항체 및 이것의 사용 방법 |
| MA50546A (fr) | 2017-06-07 | 2020-09-16 | Regeneron Pharma | Compositions et méthodes pour l'internalisation d'enzymes |
| AU2018287519B2 (en) | 2017-06-22 | 2021-07-22 | Novartis Ag | IL-1beta binding antibodies for use in treating cancer |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| CA3066779A1 (en) | 2017-06-28 | 2019-01-03 | Regeneron Pharmaceuticals, Inc. | Anti-human papillomavirus (hpv) antigen-binding proteins and methods of use thereof |
| SG11201912548XA (en) | 2017-07-06 | 2020-01-30 | Regeneron Pharma | Cell culture process for making a glycoprotein |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| JP2021500856A (ja) | 2017-09-13 | 2021-01-14 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Ｉｌ−６ｒ抗体およびその抗原結合フラグメントならびに医薬としての使用 |
| KR20200058525A (ko) | 2017-09-29 | 2020-05-27 | 리제너론 파아마슈티컬스, 인크. | 스타필로코커스 표적 항원 및 보체 성분에 결합하는 이특이적 항원-결합 분자 및 이의 용도 |
| WO2019078344A1 (ja) | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| EP4344706A3 (en) | 2017-10-30 | 2024-05-22 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| BR112020006976A2 (pt) | 2017-11-30 | 2020-10-13 | Regeneron Pharmaceuticals, Inc. | anticorpos monoclonais anti-trkb e métodos de uso |
| CN116058333A (zh) | 2017-12-05 | 2023-05-05 | 瑞泽恩制药公司 | 具有经工程改造的免疫球蛋白λ轻链的非人动物以及所述非人动物的用途 |
| SG11202004662RA (en) | 2017-12-13 | 2020-06-29 | Regeneron Pharma | Anti-c5 antibody combinations and uses thereof |
| CN111542540A (zh) | 2017-12-18 | 2020-08-14 | 瑞泽恩制药公司 | 结合瘦蛋白受体和/或gp130的双特异性抗原结合分子及其使用方法 |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| BR112020010615A2 (pt) | 2017-12-22 | 2020-10-27 | Regeneron Pharmaceuticals, Inc. | produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema |
| JP7372925B2 (ja) | 2018-01-26 | 2023-11-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インフルエンザヘマグルチニンに対するヒト抗体 |
| SG11202005235WA (en) | 2018-01-31 | 2020-07-29 | Regeneron Pharma | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| AU2019218892B2 (en) | 2018-02-07 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for therapeutic protein delivery |
| MX2020008988A (es) | 2018-02-28 | 2020-09-28 | Regeneron Pharma | Sistemas y metodos para la identificacion de contaminantes virales. |
| MA52417A (fr) | 2018-03-01 | 2021-01-06 | Regeneron Pharma | Procédés de modification de composition corporelle |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202516175A (zh) | 2018-03-19 | 2025-04-16 | 美商再生元醫藥公司 | 微晶片毛細管電泳分析及試劑 |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| MA52175A (fr) | 2018-03-26 | 2021-02-17 | Regeneron Pharma | Anticorps anti-pfrh5 et leurs fragments de liaison à l'antigène |
| KR102871690B1 (ko) | 2018-04-30 | 2025-10-16 | 리제너론 파마슈티칼스 인코포레이티드 | Her2 및/또는 aplp2에 결합하는 항체 및 이중특이적 항원-결합 분자 및 접합체 그리고 이들의 용도 |
| KR20210008008A (ko) | 2018-05-09 | 2021-01-20 | 리제너론 파마슈티칼스 인코포레이티드 | 항-msr1 항체 및 이의 사용 방법 |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| AU2019269685B2 (en) | 2018-05-17 | 2025-12-04 | Regeneron Pharmaceuticals, Inc. | Anti-CD63 antibodies, conjugates, and uses thereof |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| MA52966A (fr) | 2018-06-19 | 2021-04-28 | Regeneron Pharma | Anticorps anti-facteur xii/xiia et leurs utilisations |
| EP3810282A1 (en) | 2018-06-21 | 2021-04-28 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
| SMT202400102T1 (it) | 2018-07-19 | 2024-05-14 | Regeneron Pharma | Recettori chimerici dell’antigene con specificità per bcma e loro usi |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MX2021001549A (es) | 2018-08-10 | 2021-04-13 | Regeneron Pharma | Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera. |
| EP3840841A1 (en) | 2018-08-23 | 2021-06-30 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| CA3100035A1 (en) | 2018-08-27 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| JP7504871B2 (ja) | 2018-08-29 | 2024-06-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 関節リウマチを有する対象を治療するための方法および組成物 |
| CA3100038A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| CA3115102A1 (en) | 2018-10-23 | 2020-04-30 | Regeneron Pharmaceuticals, Inc. | Anti-npr1 antibodies and uses thereof |
| CA3117945A1 (en) * | 2018-11-09 | 2020-05-14 | University Of Massachusetts | Anti-cfae antibodies and methods of use |
| CN112867732A (zh) | 2018-11-21 | 2021-05-28 | 瑞泽恩制药公司 | 抗葡萄球菌抗体和其用途 |
| BR112021010238A2 (pt) | 2018-12-19 | 2021-08-24 | Regeneron Pharmaceuticals, Inc. | Anticorpos anti-cd28 x anti-cd22 biespecíficos e usos dos mesmos |
| JP7588586B2 (ja) | 2018-12-19 | 2024-11-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用 |
| EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| EP3908303A4 (en) * | 2019-01-07 | 2023-05-03 | Hunan Siweikang Therapeutics Co. Ltd | MODIFIED IMMUNE CELLS CO-EXPRESSING A CHIMERIC ANTIGEN RECEPTOR AND AN IL-6 ANTAGONIST TO REDUCE TOXICITY, AND USES THEREOF IN ADOPTIVE CELL THERAPY |
| MX2021008590A (es) | 2019-01-16 | 2021-08-11 | Regeneron Pharma | Metodos para caracterizar enlaces de disulfuro. |
| AU2020216978B2 (en) | 2019-01-31 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis |
| WO2020167919A1 (en) | 2019-02-12 | 2020-08-20 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
| JP2022523360A (ja) | 2019-02-21 | 2022-04-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｅｔに結合する抗ｍｅｔ抗体および二特異性抗原結合分子を使用した眼癌の治療方法 |
| WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| JP7659501B2 (ja) | 2019-03-22 | 2025-04-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ＥＧＦＲｘＣＤ２８多特異性抗体 |
| WO2020210551A1 (en) | 2019-04-10 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Human antibodies that bind ret and methods of use thereof |
| MA55760A (fr) | 2019-04-24 | 2022-03-02 | Regeneron Pharma | Procédés de diagnostic et de traitement de la polyarthrite rhumatoïde |
| SG11202111255YA (en) | 2019-05-01 | 2021-11-29 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
| MX2021013519A (es) | 2019-05-13 | 2021-12-10 | Regeneron Pharma | Ensayos de union de ligandos competitivos mejorados. |
| BR112021024445A2 (pt) | 2019-06-04 | 2022-02-15 | Regeneron Pharma | Composições e métodos para tratamento de dor em indivíduos com artrite reumatoide |
| KR20220016880A (ko) | 2019-06-05 | 2022-02-10 | 리제너론 파마슈티칼스 인코포레이티드 | 카파 유전자좌에서 발현된 제한적 람다 경쇄 레퍼토리를 갖는 비-인간 동물 및 이의 용도 |
| AU2020292283A1 (en) | 2019-06-11 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof |
| AU2020291946A1 (en) * | 2019-06-14 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| AU2020290971A1 (en) * | 2019-06-14 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| US20200405883A1 (en) | 2019-06-20 | 2020-12-31 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
| BR112022000740A2 (pt) | 2019-07-16 | 2022-07-05 | Sanofi Biotechnology | Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r |
| WO2021016585A1 (en) | 2019-07-24 | 2021-01-28 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
| KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| BR112022007923A2 (pt) | 2019-10-28 | 2022-07-26 | Regeneron Pharma | Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza |
| JP7682174B2 (ja) | 2019-11-25 | 2025-05-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 非水性エマルションを使用した持続放出製剤 |
| CA3160352A1 (en) | 2019-12-06 | 2021-06-10 | Israel Lowy | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
| AU2020398168A1 (en) | 2019-12-06 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Methods for treating COPD by administering an IL-33 antagonist |
| CN115151568A (zh) | 2019-12-23 | 2022-10-04 | 赛诺菲生物技术公司 | 用于通过施用il-33拮抗剂和/或il-4r拮抗剂以治疗或预防过敏性哮喘的方法 |
| MY200781A (en) | 2020-01-21 | 2024-01-15 | Regeneron Pharma | Deglycosylation methods for electrophoresis of glycosylated proteins |
| EP4093767A1 (en) | 2020-01-22 | 2022-11-30 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| AU2021219671A1 (en) | 2020-02-10 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Anti-Tmprss2 Antibodies and Antigen-Binding Fragments |
| MX2022009769A (es) | 2020-02-11 | 2022-11-09 | Regeneron Pharma | Anticuerpos anti-acvr1 y usos de los mismos. |
| AU2021228225A1 (en) | 2020-02-28 | 2022-09-01 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind HER2, and methods of use thereof |
| AU2021232041A1 (en) | 2020-03-06 | 2022-09-08 | Regeneron Pharmaceuticals, Inc. | Anti-GITR antibodies and uses thereof |
| KR102831970B1 (ko) | 2020-04-02 | 2025-07-11 | 리제너론 파아마슈티컬스, 인크. | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 |
| KR20230007470A (ko) * | 2020-05-06 | 2023-01-12 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Sars-cov-2 s 단백질에 결합하는 중화 항체 |
| US11884736B2 (en) | 2020-05-12 | 2024-01-30 | Regeneron Pharmaceuticals, Inc. | Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R) |
| US20230167182A1 (en) * | 2020-05-18 | 2023-06-01 | Biosion Inc. | Antibodies binding il6r and uses thereof |
| AU2021281119A1 (en) | 2020-05-26 | 2023-02-02 | Sanofi Biotechnology | Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same |
| EP4157868A1 (en) | 2020-05-26 | 2023-04-05 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| MX2022015030A (es) | 2020-05-29 | 2023-01-04 | Sanofi Biotechnology | Composiciones y metodos para el tratamiento del dolor no inflamatorio en sujetos con artritis reumatoide. |
| US20230227539A1 (en) * | 2020-06-16 | 2023-07-20 | Hifibio (Hk) Limited | Methods and compositions related to neutralizing antibodies against human coronavirus |
| WO2022032139A1 (en) * | 2020-08-07 | 2022-02-10 | Sorrento Therapeutics, Inc. | Neutralizing antibodies that bind the sars-cov-2 s protein |
| CN116249713A (zh) | 2020-08-20 | 2023-06-09 | 瑞泽恩制药公司 | 利用激活素a拮抗剂预防和治疗心功能不全和covid-19的方法 |
| EP4204449A1 (en) | 2020-08-26 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| CA3192999A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
| JP2023543152A (ja) | 2020-09-18 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用 |
| CA3194111A1 (en) | 2020-10-05 | 2022-04-14 | Christine XU | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
| JP7767411B2 (ja) | 2020-10-22 | 2025-11-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｆｇｆｒ２抗体及びその使用方法 |
| IL303027A (en) | 2020-11-25 | 2023-07-01 | Regeneron Pharma | Sustained release formulations by creating a non-aqueous membrane emulsion |
| CA3205135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| WO2022133239A1 (en) | 2020-12-18 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to npr1 agonists |
| CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| CA3202197A1 (en) | 2021-01-20 | 2022-07-28 | Reginald Smith | Methods of improving protein titer in cell culture |
| US20220404369A1 (en) | 2021-03-03 | 2022-12-22 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| WO2022187626A1 (en) | 2021-03-05 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments |
| WO2022204728A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| EP4326765A1 (en) | 2021-04-20 | 2024-02-28 | Regeneron Pharmaceuticals, Inc. | Human antibodies to artemin and methods of use thereof |
| KR20240005854A (ko) | 2021-05-04 | 2024-01-12 | 리제너론 파아마슈티컬스, 인크. | Mage-a4 특이성을 갖는 키메라 항원 수용체 및 이들의 용도 |
| EP4334353A1 (en) | 2021-05-04 | 2024-03-13 | Regeneron Pharmaceuticals, Inc. | Multispecific fgf21 receptor agonists and their uses |
| AU2022274888A1 (en) | 2021-05-11 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
| US12012450B2 (en) | 2021-06-01 | 2024-06-18 | Les Laboratoires Servier | Anti-NKG2A antibodies and compositions |
| EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| WO2023283134A1 (en) | 2021-07-05 | 2023-01-12 | Regeneron Pharmaceuticals, Inc. | Utilization of antibodies to shape antibody responses to an antigen |
| MX2024000563A (es) | 2021-07-14 | 2024-04-10 | Regeneron Pharma | Anticuerpos y fragmentos de union al antigeno anti-glicoproteína de la espícula de sars-cov-2. |
| EP4377345A1 (en) | 2021-07-26 | 2024-06-05 | Sanofi Biotechnology | Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| MX2024004108A (es) | 2021-10-07 | 2024-04-19 | Regeneron Pharma | Calibracion y correccion de medidor de ph. |
| CA3235380A1 (en) | 2021-10-20 | 2023-04-27 | Elizabeth Laws | Methods for treating prurigo nodularis by administering an il-4r antagonist |
| CA3235457A1 (en) | 2021-10-22 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Factor xi a2 domain-binding antibodies and methods of use thereof |
| IL312372A (en) | 2021-10-26 | 2024-06-01 | Regeneron Pharma | Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures |
| EP4433500A1 (en) | 2021-11-19 | 2024-09-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
| CA3239802A1 (en) | 2021-12-06 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
| US20230296559A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
| WO2023212586A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
| EP4525993A1 (en) | 2022-05-18 | 2025-03-26 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
| EP4554977A1 (en) | 2022-07-12 | 2025-05-21 | Regeneron Pharmaceuticals, Inc. | Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof |
| CN120091829A (zh) | 2022-08-29 | 2025-06-03 | 赛诺菲生物技术公司 | 通过施用il-4r拮抗剂治疗慢性诱导性寒冷性荨麻疹的方法 |
| IL320397A (en) | 2022-11-07 | 2025-06-01 | Regeneron Pharma | Antibodies binding to the catalytic domain of factor XI and methods of using them |
| US20240190978A1 (en) | 2022-11-15 | 2024-06-13 | CSBioAsset LLC | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| WO2024130165A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| EP4634659A1 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| AU2024207469A1 (en) | 2023-01-13 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| KR20250150011A (ko) | 2023-02-13 | 2025-10-17 | 리제너론 파마슈티칼스 인코포레이티드 | 항-인간 cacng1 항체를 이용한 근육 관련 장애 치료 |
| US20240299601A1 (en) | 2023-02-17 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| AU2024241290A1 (en) | 2023-03-22 | 2025-11-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist |
| WO2024229136A1 (en) | 2023-05-01 | 2024-11-07 | Regeneron Pharmaceuticals, Inc. | Multidose antibody drug products using phenol or benzyl alcohol |
| CN121039163A (zh) | 2023-05-02 | 2025-11-28 | 瑞泽恩制药公司 | 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途 |
| WO2024259206A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Cd40 x cd40 bispecific antigen-binding molecules and uses thereof |
| US20250043017A1 (en) | 2023-07-10 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF |
| WO2025014913A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Bispecific pd-l1xcd28 antibodies and methods of use thereof |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| CN119285767B (zh) * | 2023-07-10 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 抗白介素-6抗体、检测白介素-6的试剂和试剂盒 |
| WO2025019789A1 (en) | 2023-07-19 | 2025-01-23 | Regeneron Pharmaceuticals, Inc. | ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| TW202532098A (zh) | 2023-09-29 | 2025-08-16 | 美商再生元醫藥公司 | 使用控制成核之冷凍乾燥 |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025149846A1 (en) | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist |
| WO2025149845A1 (en) | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025221640A1 (en) | 2024-04-15 | 2025-10-23 | Sanofi Biotechnology | Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| CN119775414B (zh) * | 2025-03-12 | 2025-06-06 | 武汉伊莱瑞特生物科技股份有限公司 | 抗猴白介素-6单克隆抗体、酶联免疫检测试剂盒及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2694767A1 (fr) * | 1992-08-13 | 1994-02-18 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
| EP0409607B1 (en) * | 1989-07-20 | 1996-10-30 | Tadamitsu Kishimoto | Antibody to human interleukin-6 receptor |
| US20050142635A1 (en) * | 1991-04-25 | 2005-06-30 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human antibody to human interleukin-6 receptor |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| CA1341152C (en) * | 1988-01-22 | 2000-12-12 | Tadamitsu Kishimoto | Receptor protein for human b cell stimulatory factor-2 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JPH05227970A (ja) * | 1992-02-19 | 1993-09-07 | Chugai Pharmaceut Co Ltd | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| JPH09505721A (ja) | 1992-10-20 | 1997-06-10 | シータス オンコロジー コーポレイション | インターロイキン６レセプターアンタゴニスト |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| AU7967294A (en) * | 1993-10-06 | 1995-05-01 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
| ATE552012T1 (de) | 1994-10-07 | 2012-04-15 | Chugai Pharmaceutical Co Ltd | Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff |
| EP0791359A4 (en) * | 1994-10-21 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES |
| EP0800829B2 (en) | 1994-12-29 | 2012-07-25 | Chugai Seiyaku Kabushiki Kaisha | Use of a pm-1 antibody or of a mh 166 antibody for enhancing the anti-tumor effect of cisplatin or carboplatin |
| ES2264135T3 (es) * | 1995-02-13 | 2006-12-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6. |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US5785965A (en) | 1996-05-15 | 1998-07-28 | The Board Of Trustees Of The Leland Stanford Junior Univ. | VEGF gene transfer into endothelial cells for vascular prosthesis |
| EP0923941B1 (en) | 1996-06-27 | 2006-05-17 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| US20020187150A1 (en) * | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| DE69839517D1 (de) | 1997-08-15 | 2008-07-03 | Chugai Pharmaceutical Co Ltd | Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus |
| CA2324115C (en) | 1998-03-17 | 2008-12-23 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient |
| DK1108435T3 (da) | 1998-08-24 | 2007-02-05 | Chugai Pharmaceutical Co Ltd | Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| EP2311492B1 (en) | 2000-08-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing stabilized preparations |
| CA2424371A1 (en) | 2000-10-20 | 2003-04-01 | Chugai Seiyaku Kabushiki Kaisha | Agonistic monoclonal antibody fragments |
| AU1095202A (en) * | 2000-10-25 | 2002-05-06 | Chugai Pharmaceutical Co Ltd | Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist |
| WO2002036165A1 (fr) * | 2000-10-27 | 2002-05-10 | Chugai Seiyaku Kabushiki Kaisha | Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| UA80091C2 (en) * | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| US20060275294A1 (en) * | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078533A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US20060078532A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078531A1 (en) * | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| CN1678744B (zh) * | 2002-08-30 | 2010-05-26 | 财团法人化学及血清疗法研究所 | 人的抗人白细胞介素-6抗体以及所述抗体的片段 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| WO2005028514A1 (en) | 2003-09-22 | 2005-03-31 | Biovation Gmbh & Co. Kg. | Use of a compound for reducing the biological effectiveness of il-6 |
| US8617550B2 (en) * | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| JP2008505054A (ja) * | 2004-02-11 | 2008-02-21 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Ｉｌ−６アンタゴニストで骨関節炎を治療する方法 |
| US20070036788A1 (en) * | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| JPWO2006046661A1 (ja) * | 2004-10-28 | 2008-05-22 | 国立大学法人大阪大学 | インターロイキン−６阻害剤 |
| JP2008524242A (ja) * | 2004-12-16 | 2008-07-10 | ジェネンテック・インコーポレーテッド | 自己免疫障害を治療する方法 |
| WO2007094754A2 (en) * | 2005-01-27 | 2007-08-23 | The Regents Of The University Of Califordnia | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| NZ573557A (en) * | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| RU2319351C1 (ru) * | 2006-09-13 | 2008-03-20 | Олег Иванович Квасенков | Способ подготовки к хранению яблок свежих специального назначения |
| JP2010507624A (ja) | 2006-10-27 | 2010-03-11 | アブリンクス エン．ヴェー． | ポリペプチド及びタンパク質の鼻内送達 |
| EP2666787B1 (en) | 2007-05-31 | 2022-02-09 | Genmab A/S | STABLE IgG4 ANTIBODIES |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2009109584A1 (en) | 2008-03-07 | 2009-09-11 | Ferring International Center S. A. | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX |
-
2007
- 2007-06-01 NZ NZ573557A patent/NZ573557A/en unknown
- 2007-06-01 US US11/809,482 patent/US7582298B2/en active Active
- 2007-06-01 MX MX2008014804A patent/MX2008014804A/es active IP Right Grant
- 2007-06-01 JP JP2009513324A patent/JP5307708B2/ja active Active
- 2007-06-01 AU AU2007254831A patent/AU2007254831B2/en active Active
- 2007-06-01 EP EP11171039A patent/EP2374818B1/en active Active
- 2007-06-01 ES ES11171039T patent/ES2398076T3/es active Active
- 2007-06-01 PL PL11171039T patent/PL2374818T3/pl unknown
- 2007-06-01 MY MYPI20084757A patent/MY147468A/en unknown
- 2007-06-01 DK DK07777380.2T patent/DK2041177T3/da active
- 2007-06-01 SI SI200730858T patent/SI2041177T1/sl unknown
- 2007-06-01 CN CN2012100596311A patent/CN102585002A/zh active Pending
- 2007-06-01 PT PT111710398T patent/PT2374818E/pt unknown
- 2007-06-01 CA CA2652976A patent/CA2652976C/en active Active
- 2007-06-01 BR BRPI0712224A patent/BRPI0712224B8/pt active IP Right Grant
- 2007-06-01 NZ NZ587107A patent/NZ587107A/en unknown
- 2007-06-01 PT PT07777380T patent/PT2041177E/pt unknown
- 2007-06-01 PL PL07777380T patent/PL2041177T3/pl unknown
- 2007-06-01 MY MYPI2012001581A patent/MY159787A/en unknown
- 2007-06-01 EP EP07777380A patent/EP2041177B1/en active Active
- 2007-06-01 RS RS20120074A patent/RS52176B/sr unknown
- 2007-06-01 AT AT07777380T patent/ATE537190T1/de active
- 2007-06-01 HR HR20120175T patent/HRP20120175T1/hr unknown
- 2007-06-01 WO PCT/US2007/013062 patent/WO2007143168A2/en not_active Ceased
- 2007-06-01 RS RS20130051A patent/RS52643B/sr unknown
- 2007-06-01 ES ES07777380T patent/ES2377579T3/es active Active
- 2007-06-01 DK DK11171039.8T patent/DK2374818T3/da active
- 2007-06-01 CN CN200780019546XA patent/CN101454345B/zh active Active
- 2007-06-01 RU RU2008152443/10A patent/RU2433138C2/ru active
- 2007-06-01 ME MEP-2008-853A patent/ME00519B/me unknown
- 2007-06-01 SI SI200731155T patent/SI2374818T1/sl unknown
-
2008
- 2008-11-19 IL IL195393A patent/IL195393A/en active IP Right Grant
- 2008-11-26 CR CR10462A patent/CR10462A/es unknown
- 2008-11-28 SV SV2008003113A patent/SV2008003113A/es unknown
- 2008-12-02 GT GT200800272A patent/GT200800272A/es unknown
- 2008-12-02 TN TNP2008000502A patent/TNSN08502A1/en unknown
- 2008-12-05 KR KR1020087029749A patent/KR101464502B1/ko active Active
- 2008-12-18 NO NO20085309A patent/NO340778B1/no active Protection Beyond IP Right Term
-
2009
- 2009-07-13 US US12/501,657 patent/US8043617B2/en active Active
-
2011
- 2011-09-12 US US13/230,081 patent/US8183014B2/en active Active
-
2012
- 2012-03-07 CY CY20121100231T patent/CY1112456T1/el unknown
- 2012-04-18 US US13/450,011 patent/US20130157313A1/en not_active Abandoned
-
2013
- 2013-02-21 CY CY20131100159T patent/CY1113708T1/el unknown
- 2013-03-15 HR HRP20130228TT patent/HRP20130228T1/hr unknown
- 2013-05-15 JP JP2013102655A patent/JP5805703B2/ja active Active
-
2014
- 2014-03-12 US US14/206,259 patent/US20140255995A1/en not_active Abandoned
-
2015
- 2015-09-01 JP JP2015171640A patent/JP6140777B2/ja active Active
-
2016
- 2016-04-22 US US15/136,152 patent/US9884916B2/en active Active
-
2017
- 2017-11-13 CY CY2017039C patent/CY2017039I1/el unknown
- 2017-11-14 NO NO2017060C patent/NO2017060I1/no unknown
- 2017-11-15 NL NL300911C patent/NL300911I2/nl unknown
- 2017-11-22 LU LU00050C patent/LUC00050I2/en unknown
- 2017-11-23 LT LTPA2017038C patent/LTC2041177I2/lt unknown
- 2017-12-01 HU HUS1700050C patent/HUS1700050I1/hu unknown
-
2018
- 2018-08-31 US US16/119,695 patent/US10584173B2/en active Active
-
2020
- 2020-01-28 US US16/774,945 patent/US11370843B2/en active Active
-
2022
- 2022-05-20 US US17/749,728 patent/US20230094591A1/en not_active Abandoned
-
2024
- 2024-11-01 US US18/935,325 patent/US20250206829A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0409607B1 (en) * | 1989-07-20 | 1996-10-30 | Tadamitsu Kishimoto | Antibody to human interleukin-6 receptor |
| US20050142635A1 (en) * | 1991-04-25 | 2005-06-30 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human antibody to human interleukin-6 receptor |
| FR2694767A1 (fr) * | 1992-08-13 | 1994-02-18 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11370843B2 (en) | High affinity antibodies to human IL-6 receptor | |
| US8338135B2 (en) | High affinity human antibodies to human IL-4 receptor | |
| HK1173456A (en) | High affinity antibodies to human il-6 receptor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| NC | Extension of term for standard patent requested (sect. 70) |
Free format text: PRODUCT NAME: KEVZARA SARILUMAB Filing date: 20180914 |
|
| NDA | Extension of term for standard patent accepted (sect.70) |
Free format text: PRODUCT NAME: KEVZARA SARILUMAB Filing date: 20180914 |
|
| NDB | Extension of term for standard patent granted (sect.76) |
Free format text: PRODUCT NAME: KEVZARA SARILUMAB Filing date: 20180914 Extension date: 20320601 |